11.87
Precedente Chiudi:
$11.73
Aprire:
$11.7
Volume 24 ore:
325.72K
Relative Volume:
0.39
Capitalizzazione di mercato:
$4.45B
Reddito:
$4.79B
Utile/perdita netta:
$-317.00M
Rapporto P/E:
-13.04
EPS:
-0.91
Flusso di cassa netto:
$-59.00M
1 W Prestazione:
-2.70%
1M Prestazione:
+5.14%
6M Prestazione:
-33.43%
1 anno Prestazione:
-20.50%
Bausch Lomb Corp Stock (BLCO) Company Profile
Nome
Bausch Lomb Corp
Settore
Industria
Telefono
908-541-5456
Indirizzo
520 APPLEWOOD CRESCENT, VAUGHAN
Confronta BLCO con altri titoli
Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
---|---|---|---|---|---|---|
![]()
BLCO
Bausch Lomb Corp
|
11.87 | 4.45B | 4.79B | -317.00M | -59.00M | -0.91 |
![]()
ISRG
Intuitive Surgical Inc
|
509.98 | 189.82B | 8.71B | 2.48B | 1.75B | 6.82 |
![]()
BDX
Becton Dickinson Co
|
168.28 | 49.98B | 20.87B | 1.50B | 2.59B | 5.24 |
![]()
ALC
Alcon Inc
|
84.91 | 44.00B | 9.93B | 1.12B | 1.58B | 2.25 |
![]()
RMD
Resmed Inc
|
253.05 | 37.05B | 5.02B | 1.31B | 1.56B | 8.91 |
![]()
WST
West Pharmaceutical Services Inc
|
216.17 | 16.36B | 2.90B | 467.20M | 306.90M | 6.37 |
Bausch Lomb Corp Stock (BLCO) Upgrades & Downgrades
Data | Azione | Analista | Modifica della valutazione |
---|---|---|---|
2025-05-02 | Reiterato | H.C. Wainwright | Buy |
2025-03-28 | Downgrade | Wells Fargo | Overweight → Equal Weight |
2024-12-11 | Downgrade | Citigroup | Buy → Neutral |
2024-12-02 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
2024-10-15 | Aggiornamento | Evercore ISI | In-line → Outperform |
2024-07-10 | Iniziato | Raymond James | Outperform |
2024-05-06 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
2024-01-04 | Downgrade | Evercore ISI | Outperform → In-line |
2023-12-12 | Iniziato | Stifel | Hold |
2023-10-03 | Ripresa | Evercore ISI | Outperform |
2023-05-30 | Ripresa | Morgan Stanley | Equal-Weight |
2023-03-09 | Iniziato | Needham | Hold |
2022-12-21 | Iniziato | Barclays | Equal Weight |
2022-09-12 | Iniziato | H.C. Wainwright | Buy |
2022-07-26 | Iniziato | RBC Capital Mkts | Outperform |
2022-06-24 | Iniziato | Evercore ISI | Outperform |
2022-06-06 | Iniziato | Citigroup | Buy |
2022-05-31 | Iniziato | Deutsche Bank | Hold |
2022-05-31 | Iniziato | Goldman | Neutral |
2022-05-31 | Iniziato | Guggenheim | Buy |
2022-05-31 | Iniziato | JP Morgan | Neutral |
2022-05-31 | Iniziato | Jefferies | Buy |
2022-05-31 | Iniziato | Morgan Stanley | Equal-Weight |
2022-05-31 | Iniziato | Wells Fargo | Overweight |
2022-05-11 | Iniziato | Cowen | Outperform |
Mostra tutto
Bausch Lomb Corp Borsa (BLCO) Ultime notizie
Bausch + Lomb prices €675 million in senior secured notes - Investing.com
Bausch + Lomb Upsizes Note Offering And Secures New Loans - Finimize
Bausch + Lomb Strengthens Financial Position with €675M Notes and $3.1B Credit Package - Stock Titan
Bausch + Lomb announces €600m senior secured notes offering - Investing.com
Bausch + Lomb Has Promising Growth, But Lower Entry Points Likely Soon - Seeking Alpha
Bausch + Lomb’s SWOT analysis: ophthalmology leader faces headwinds in stock outlook - Investing.com
Bausch + Lomb Announces Launch of Senior Secured Notes Offering and Refinancing of Credit Agreement - BioSpace
Bausch + Lomb (NYSE:BLCO) Price Target Cut to $16.00 by Analysts at Barclays - Defense World
Kalkine: Examines Bausch + Lomb (NYSE:BLCO) and Its Dividend Yield Signals - Kalkine Media
Bausch & Lomb (BLCO) Price Target Revised by Barclays Analyst | - GuruFocus
Bausch & Lomb (BLCO) Price Target Revised by Barclays Analyst | BLCO Stock News - GuruFocus
Bausch + Lomb (BLCO) Price Target Reduced by Barclays Analyst | - GuruFocus
Barclays reduces Bausch & Lomb stock price target to $16 - Investing.com Australia
Barclays reduces Bausch & Lomb stock price target to $16 By Investing.com - Investing.com Nigeria
BLCO Investors Have Opportunity to Join Bausch + Lomb Corporation Fraud Investigation with the Schall Law Firm - Business Wire
Innovations in Imaging, such as AI-Enhanced Retinal & Fundus Camera Systems are Booming Along with Revenue Opportunities - GlobeNewswire Inc.
Bausch + Lomb (BLCO) Introduces New Lubricating Eye Drops in U.S - GuruFocus
Breakthrough Eye Drops: Bausch + Lomb Launches First-Ever Vitamin-Enriched Formula for Dry Eye Relief - Stock Titan
Bausch + Lomb Co. (NYSE:BLCO) Short Interest Update - Defense World
Bausch + Lomb Co. (NYSE:BLCO) Given Consensus Recommendation of “Hold” by Brokerages - Defense World
Bausch & Lomb Corp (BLCO) Trading Down 3.41% on May 30 - GuruFocus
Cetera Investment Advisers Decreases Stock Holdings in Bausch + Lomb Co. (NYSE:BLCO) - Defense World
Public market insider buying at Bausch + Lomb (BLCO) - The Globe and Mail
Bausch + Lomb, Organon, Globalstar, Telephone and Data Systems, and nLIGHT Shares Skyrocket, What You Need To Know - Yahoo Finance
Bausch + Lomb’s SWOT analysis: stock outlook amid market challenges - Investing.com
Bausch + Lomb to Participate in the 2025 Jefferies Global Healthcare Conference - BioSpace
Bausch & Lomb shareholders approve board nominees and compensation - Investing.com
Bausch + Lomb shareholders elect 10 directors at annual meeting By Investing.com - Investing.com India
Bausch + Lomb shareholders elect 10 directors at annual meeting - Investing.com
Bausch + Lomb Announces 2025 Annual Meeting of Shareholders Results - Yahoo Finance
Bausch + Lomb (BLCO) Launches LUMIFY Preservative Free Eye Drops in the U.S. | BLCO Stock News - GuruFocus
Bausch + Lomb introduces Zenlens CHROMA HOA lenses By Investing.com - Investing.com Canada
Bausch + Lomb introduces Zenlens CHROMA HOA lenses - Investing.com
Bausch + Lomb Launches Zenlens® CHROMA HOA™ in the United States - The Joplin Globe
Bausch + Lomb Co. (NYSE:BLCO) Given Average Recommendation of “Hold” by Analysts - Defense World
Morgan Stanley Lowers Bausch + Lomb (NYSE:BLCO) Price Target to $12.00 - Defense World
Bausch + Lomb’s LuxLife Intraocular Lens Gains European CE Mark Approval - TipRanks
Bausch + Lomb (BLCO) Receives CE Mark for LuxLife Intraocular Lens | BLCO Stock News - GuruFocus
Bausch + Lomb Receives European CE Mark Approval for Preloaded LuxLife® Full Range of Vision Intraocular Lens - Stock Titan
Bausch & Lomb (BLCO) Price Target Lowered by Morgan Stanley | BLCO Stock News - GuruFocus
Bausch & Lomb (BLCO) Price Target Lowered by Morgan Stanley | BL - GuruFocus
20,600 Shares in Bausch + Lomb Co. (NYSE:BLCO) Bought by Renaissance Technologies LLC - Defense World
Citigroup Issues Pessimistic Forecast for Bausch + Lomb (NYSE:BLCO) Stock Price - Defense World
Bausch & Lomb stock target cut to $15 at H.C. Wainwright By Investing.com - Investing.com South Africa
Bausch & Lomb stock target cut to $15 at H.C. Wainwright - Investing.com Nigeria
Bausch & Lomb (BLCO) Receives Adjusted Price Target by HC Wainwr - GuruFocus
Bausch & Lomb (BLCO) Receives Adjusted Price Target by HC Wainwright & Co. | BLCO Stock News - GuruFocus
Bausch + Lomb (BLCO) Price Target Cut by Analyst Amid Tariff Concerns | BLCO Stock News - GuruFocus
Citi Maintains Neutral Rating on Bausch & Lomb (BLCO), Lowers Pr - GuruFocus
Citi Maintains Neutral Rating on Bausch & Lomb (BLCO), Lowers Price Target | BLCO Stock News - GuruFocus
Bausch + Lomb (BLCO) Shares Plunge After Weak Q1 2025 Results - GuruFocus
Bausch Lomb Corp Azioni (BLCO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Bausch Lomb Corp Azioni (BLCO) insider trading
Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
---|---|---|---|---|---|---|---|
VON ESCHENBACH ANDREW C. | Director |
May 02 '25 |
Buy |
11.76 |
1,695 |
19,925 |
41,748 |
SAUNDERS BRENT L | CEO and Chairman of the Board |
Aug 05 '24 |
Buy |
15.66 |
32,250 |
505,067 |
595,169 |
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):